Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$29.68 +1.50%

+$0.50 today

Market cap
$1.78B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.60M

Average 1.11M

AGIO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Agios Pharmaceuticals, Inc.NASDAQ: AGIO

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -477.7%

Net margin was -477.7% in Q1 FY2026, up 545.5 pp from a year earlier. On a trailing-twelve-month basis it was -639.8%, down 2438.1 pp year over year. Over 3 fiscal years it widened by 863.8 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of -180.6% for the fiscal year ending Dec 2026, up from -764.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-477.7%+63.4 pp QoQ
Last fiscal yearDec 2025
-764.0%-2609.9 pp YoY
LTMMar 2026
-639.8%-2438.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+545.5 pp+525.1 pp-20.4 pp
1 year-2609.9 pp+583.5 pp+3193.4 pp
3 years+863.8 pp+747.2 pp-116.6 pp
5 years+777.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-764.0%
Year-over-year change
-2609.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How AGIO compares with its peers on the latest reported figures

  • AGIO's LTM Mar 2026 net margin of -639.8% is the lowest of the 6 companies compared; the peer median is -40.9%.
  • Its year-over-year change of -2438.1 pp is the lowest of 6, against a peer median of -34.5 pp.
  • Over three fiscal years its change of +863.8 pp compares with a peer median of +119.4 pp.
AGIO Competitors Peer median
Net Margin for AGIO and competitors
Company Period LTM level YoY 3-year change
PHARPharming Group N.V.LTM Mar 20263.3% +7.7 pp-5.9 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-3.8% -39.5 pp+119.4 pp
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-40.9% -34.5 pp+121.4 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-91.0% +2.0 pp+109.3 pp
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026-139.2% -125.5 pp+171.6 pp
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026-639.8% -2438.1 pp+863.8 pp
IRONDisc Medicine, Inc.FY2025— ——
Peer median (excluding AGIO) -40.9%-34.5 pp+119.4 pp

Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue014.24M26.82M36.5M54.03M
Cost of Revenue18.78M1.7M9.5M4.17M11.52M
Gross Profit(18.78M)12.54M17.32M32.33M42.51M
Gross Margin—88.0%64.6%88.6%78.7%
Research & Development256.97M279.91M288.9M301.29M334.36M
Selling, General & Admin121.45M121.67M119.9M156.78M180.28M
Operating Expenses359.64M401.58M408.81M458.07M514.64M
Depreciation & Amortization18.78M8.56M6.62M5.65M5.18M
EBITDA(337.73M)(223.24M)(345.47M)723.62M(408.62M)
EBITDA Margin—-1567.7%-1287.9%1982.6%-756.3%
Operating Income(378.42M)(389.05M)(391.49M)(425.74M)(472.13M)
Operating Margin—-2732.1%-1459.5%-1166.5%-873.9%
Interest Income836K12.79M33.34M48.08M56.38M
Interest Expense00000
Other Income / Expenses21.91M157.25M39.4M1.14B58.34M
Income Before Tax(356.51M)(231.8M)(352.09M)717.97M(413.8M)
Pre-Tax Margin—-1627.8%-1312.6%1967.1%-765.9%
Income Tax Expense00044.24M(1.02M)
Net Income1.6B(231.8M)(352.09M)673.73M(412.78M)
Net Margin—-1627.8%-1312.6%1845.9%-764.0%
EPS (Basic)(6.36)(4.23)(6.33)11.86(7.12)
EPS (Diluted)(6.36)(4.23)(6.33)11.64(7.12)
Weighted Avg Shares60.45M54.79M55.65M56.81M57.97M
Weighted Avg Shares (Diluted)60.45M54.79M55.65M57.89M57.97M

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.